Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
mr. market has no clue about dyai and their role. who knows if this vaccine is the one dyai is working on. hopefully someone asks mark next thursday. so far the stock price has held up pretty well so at least no one is selling. many small bios have been hit hard lately. we will see. big earnings call thursday. mark needs to deliver. i wonder if he says anything about sanofi. presumably if they walked, he would advise thursday
Stock was down like $40 and now up lol
$VTGN prices 15.6m shares at $.80/share
Moderna Announces Resignation of Dr. Elizabeth Nabel From Board of Directors
https://www.businesswire.com/news/home/20200730006042/en/
Dyadic to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020
JUPITER, FL / ACCESSWIRE / July 30, 2020 -- Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended June 30, 2020 after the market close on Thursday, August 13, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.
Yes, the presentation was very positive and it’s great to see them get the grant. Obtaining more funding through darpa will be great. If they can land a big pharmaceutical deal with a sizeable upfront payment, it could be a game changer. It sounds like they are close. Hopefully we see something significant soon
Nice find
Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis :: Aurinia Pharmaceuticals Inc. (AUPH)
ACAD fail ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
#FAIL
maybe there's reason for him to feel confident?
I would think so
Thank you so much!
Looks interesting. Any quick DD you can share? Seems undervalued. I see the covid programs. Any others? Nice platform
Anyone following BEAM? Thoughts?
Bioasis/Chiesi webcast, July 16.
if he can get funding from warp speed the stock should explode. i am encouraged with their role in the covid space but i want to see progress in their other programs. if you listened to the last earnings call, it appeared that things were on the verge of breaking. i wonder what sanofi does. do they walk or continue with us? i would be surprised if they walked given the results mark has told us C1 provided to them plus all of these other deals dyai is working on, you'd think sanofi would not want to abandon dyai right now. maybe we get a tbio type deal
yeah, i see that but it hit my feed earlier. either way, nice news. good to see the 4th leading animal health company is now on board. not much of a move higher. my guess is either people knew about it yesterday and ran it up and/or people want to see mark monatize it and since there's very little detail to the PR, as always, investors who do not follow the story didn't find it "sexy" enough
i have a free SA membership but it did show up on my yahoo finance feed as well
it came up on my news feed.
VVUS files for bankruptcy
Yikes. Sold that one a long time ago
Eh, that’s fine. I want mark to announce a deal with upfront payment or at least something substantial. We need good news. There was a lot he discussed on the last earnings call. Need to see this come to fruition
It depends which stocks you own.
On June 24, 2020, Dyadic International, Inc. (“Dyadic” or the “Company”) entered into an Amended and Restated Non-Exclusive Sub-License Agreement (the “Amended Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”) to amend and restate the prior agreement dated May 5, 2019.
Under the terms of the Amended Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a non-exclusive sub-license to certain patent rights and know-how related to Dyadic's proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.